BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 14516190)

  • 1. RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element.
    Luedtke NW; Liu Q; Tor Y
    Biochemistry; 2003 Oct; 42(39):11391-403. PubMed ID: 14516190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region.
    Wang Y; Hamasaki K; Rando RR
    Biochemistry; 1997 Jan; 36(4):768-79. PubMed ID: 9020774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors.
    Luedtke NW; Tor Y
    Biopolymers; 2003 Sep; 70(1):103-19. PubMed ID: 12925996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity in the binding of aminoglycosides to HIV-RRE RNA.
    Cho J; Rando RR
    Biochemistry; 1999 Jun; 38(26):8548-54. PubMed ID: 10387102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA.
    Daly TJ; Doten RC; Rusche JR; Auer M
    J Mol Biol; 1995 Oct; 253(2):243-58. PubMed ID: 7563086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine side-chain dynamics in the HIV-1 rev-RRE complex.
    Wilkinson TA; Botuyan MV; Kaplan BE; Rossi JJ; Chen Y
    J Mol Biol; 2000 Nov; 303(4):515-29. PubMed ID: 11054288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.
    Nam YS; Petrovic A; Jeong KS; Venkatesan S
    J Virol; 2001 Mar; 75(6):2957-71. PubMed ID: 11222721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-triggered conformational switch in HIV-1 RRE RNA complexes.
    Gosser Y; Hermann T; Majumdar A; Hu W; Frederick R; Jiang F; Xu W; Patel DJ
    Nat Struct Biol; 2001 Feb; 8(2):146-50. PubMed ID: 11175904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide.
    Peterson RD; Feigon J
    J Mol Biol; 1996 Dec; 264(5):863-77. PubMed ID: 9000617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives.
    Ratmeyer L; Zapp ML; Green MR; Vinayak R; Kumar A; Boykin DW; Wilson WD
    Biochemistry; 1996 Oct; 35(42):13689-96. PubMed ID: 8885849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of HIV Rev peptides with the Rev response element RNA.
    Williamson JR; Battiste JL; Mao H; Frankel AD
    Nucleic Acids Symp Ser; 1995; (33):46-8. PubMed ID: 8643394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dynamic in vivo view of the HIV-I Rev-RRE interaction.
    Charpentier B; Stutz F; Rosbash M
    J Mol Biol; 1997 Mar; 266(5):950-62. PubMed ID: 9086273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mismatch-binding ligands as inhibitors for Rev-RRE interaction.
    Nakatani K; Horie S; Goto Y; Kobori A; Hagihara S
    Bioorg Med Chem; 2006 Aug; 14(15):5384-8. PubMed ID: 16603366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy.
    Lacourciere KA; Stivers JT; Marino JP
    Biochemistry; 2000 May; 39(19):5630-41. PubMed ID: 10801313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence specificity in the higher-order interaction of the Rev protein of HIV-1 with its target sequence, the RRE.
    Powell DM; Zhang MJ; Konings DA; Wingfield PT; Stahl SJ; Dayton ET; Dayton AI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):317-23. PubMed ID: 7552493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
    DeJong ES; Chang CE; Gilson MK; Marino JP
    Biochemistry; 2003 Jul; 42(26):8035-46. PubMed ID: 12834355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural dynamics of HIV-1 Rev and its complexes with RRE and 5S RNA.
    Lam WC; Seifert JM; Amberger F; Graf C; Auer M; Millar DP
    Biochemistry; 1998 Feb; 37(7):1800-9. PubMed ID: 9485305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy.
    Lapidot A; Vijayabaskar V; Litovchick A; Yu J; James TL
    FEBS Lett; 2004 Nov; 577(3):415-21. PubMed ID: 15556620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding kinetics and bioassay of RRE mRNA fragments to a peptide containing the recognition domain of HIV-1 Rev.
    West ML; Ramsdale TE
    Biomed Pept Proteins Nucleic Acids; 1996-1997; 2(3):85-8. PubMed ID: 9575345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
    Sugaya M; Nishino N; Katoh A; Harada K
    J Pept Sci; 2008 Aug; 14(8):924-35. PubMed ID: 18351707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.